Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will join Cowen's 42nd Annual Healthcare Conference for a panel discussion and investor meetings from March 7-9, 2022. The panel, focusing on Gastrointestinal/Genitourinary Oncology, is scheduled for March 8, 2022, at 10:30 AM ET. Cardiff is advancing its lead drug, onvansertib, a third-generation PLK1 inhibitor, aimed at treating various cancers including KRAS-mutated colorectal cancer. A replay of the panel will be accessible on Cardiff's website for 30 days post-conference.

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a panel discussion and one-on-one investor meetings at Cowen's 42^nd Annual Healthcare Conference taking place virtually March 7-9, 2022.  

Details on the panel can be found below.

Cowen 42nd Annual Healthcare Conference
Date:	March 8, 2022
Time:	10:30 AM ET
Topic:	Gastrointestinal/Genitourinary Oncology Panel
Webcast Link:	https://wsw.com/webcast/cowen108/panel11/2319930

A replay of the panel discussion will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 30 days after the conference's conclusion.  

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is the third generation PLK1 inhibitor onvansertib, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com 

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-participate-in-cowens-42nd-annual-healthcare-conference-301492623.html

SOURCE Cardiff Oncology, Inc.

FAQ

When will Cardiff Oncology participate in the Cowen 42nd Annual Healthcare Conference?

Cardiff Oncology will participate in the Cowen 42nd Annual Healthcare Conference from March 7-9, 2022.

What is the date and time of Cardiff Oncology's panel discussion?

The panel discussion for Cardiff Oncology is scheduled for March 8, 2022, at 10:30 AM ET.

What is the focus of Cardiff Oncology's panel at the conference?

The focus of Cardiff Oncology's panel is on Gastrointestinal/Genitourinary Oncology.

What is onvansertib and what cancers is it targeting?

Onvansertib is Cardiff Oncology's lead drug, a third-generation PLK1 inhibitor targeting cancers such as KRAS-mutated colorectal cancer.

Where can I find the replay of Cardiff Oncology's panel discussion?

The replay of Cardiff Oncology's panel discussion will be available on the Cardiff Oncology website for 30 days after the conference.